ChiCTR2200057994 版本V1.2 版本创建时间2023/07/06 17:29:29 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200057994 

最近更新日期:

Date of Last Refreshed on:

2023-02-28 09:49:19 

注册时间:

Date of Registration:

2022-03-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

慢性颞叶癫痫相关性抑郁的生化标记的临床研究

Public title:

A clinical study of biochemical markers of depression associated with chronic temporal lobe epilepsy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

慢性颞叶癫痫相关性抑郁的生化标记的临床研究

Scientific title:

A clinical study of biochemical markers of depression associated with chronic temporal lobe epilepsy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

骆华正 

研究负责人:

蔡伦 

Applicant:

Huazheng Luo 

Study leader:

Lun Cai 

申请注册联系人电话:

Applicant telephone:

+86 16657141216

研究负责人电话:

Study leader's
telephone:

+86 13768301934

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

757653827@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zaozhi322@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广西壮族自治区南宁市青秀区东葛路89-9号

研究负责人通讯地址:

广西壮族自治区南宁市青秀区东葛路89-9号

Applicant address:

89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region

Study leader's address:

89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广西中医药大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Guangxi University of Chinese Medicine

研究负责人所在单位:

广西中医药大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Guangxi University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审2021-048-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广西中医药大学第一附属医院伦理委员会

Name of the ethic committee:

IEC for The First Affiliated Hospital of Guangxi University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022-02-17 00:00:00

伦理委员会联系人:

黎军宏

Contact Name of the ethic committee:

Junhong Li

伦理委员会联系地址:

广西壮族自治区南宁市青秀区东葛路89-9号

Contact Address of the ethic committee:

89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广西中医药大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Guangxi University of Chinese Medicine

研究实施负责(组长)单位地址:

广西壮族自治区南宁市青秀区东葛路89-9号

Primary sponsor's address:

89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广西壮族自治区

市(区县):

南宁

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

Nanning

单位(医院):

广西中医药大学第一附属医院

具体地址:

广西壮族自治区南宁市青秀区东葛路89-9号

Institution
hospital:

The First Affiliated Hospital of Guangxi University of Chinese Medicine

Address:

89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region

经费或物资来源:

广西自然科学基金

Source(s) of funding:

Guangxi Natural Science Foundation

研究疾病:

癫痫相关性抑郁  

Target disease:

Epilepsy associated depression

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

试图证实慢性颞叶癫痫并发抑郁的患者外周血中IDO激活及IDO激活后外周血和尿液中色氨酸代谢产物3-HAA、3-HK浓度增加和KYN/TRY、QUIN/KYNA比值升高,粪便中肠道菌群改变,并且这些生化标记与抑郁评分相关。从临床患者身上证实IDO激活后色氨酸代谢产物3-HAA、3-HK浓度增加和KYN/TRY、QUIN/KYNA比值升高,肠道菌群改变是癫痫相关的抑郁的原因和生化标记。通过证实此通路,了解颞叶癫痫相关性抑郁的机制,并为癫痫相关性抑郁的诊断和防治提供理论依据。  

Objectives of Study:

The purpose of this study was to confirm that the concentrations of tryptophan metabolites 3-HAA and 3-HK in peripheral blood and urine and the ratio of KYN/TRY to QUIN/KYNA in peripheral blood and urine increased after IDO activation and IDO activation in patients with chronic temporal lobe epilepsy complicated with depression, and these biochemical markers were related to depression score. It was confirmed from clinical patients that the concentration of tryptophan metabolites 3-HAA, 3-HK and the ratio of KYN/TRY to QUIN/KYNA increased after IDO activation, and the change of intestinal flora was the cause and biochemical marker of epilepsy-related depression. By confirming this pathway, we can understand the mechanism of temporal lobe epilepsy-related depression and provide the theoretical basis for the diagnosis, prevention, and treatment of epilepsy-related depression.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄18-65岁,无性别限制;
2. 符合经典的 1989 年国际抗癫痫联盟关于癫痫和癫痫综合征的分类标准:
(1)临床发作症状提示致痫病灶位于颞叶;
(2)发作期或发作间期脑电图(electroencephalograph ,EEG)提示痫性病灶位于颞叶或起源于颞叶;
(3)未接受过抗抑郁药物;
3. 抑郁发作诊断标准符合精神疾病诊断与统计手册第4版(The Diagnostic and Statistical Manual of Mental Disorders IV,DSM-IV)中分类与相关诊断标准;
4. 汉密尔顿抑郁量表(HAMD)17 项评分≥17分且<24分;
5. 所有受试者或其监护人知情同意,愿意参与并签署知情同意书。

单一的颞叶癫痫患者目前诊断当前应符合1、2条件。
颞叶癫痫伴发抑郁的患者目前诊断应符合1、2、3、4条件;且诊断为伴有抑郁发作(包括初次发作和复发)而未服用药物;癫痫诊断早于初次抑郁发作半年以上。
正常对照组:正常的健康志愿者。半年内无痫性发作和抑郁发作出现。

Inclusion criteria

1. Age 18-65 years, no gender restriction;
2. Meet the classic 1989 International League Against Epilepsy classification criteria for epilepsy and epileptic syndromes:
(1) Clinical seizure symptoms suggesting that the epileptogenic lesion is located in the temporal lobe;
(2) Electroencephalograph (EEG) during the seizure or interictal period suggests that the epileptic lesion is located in or originates from the temporal lobe;
(3) No antidepressant medication was received;
3. The diagnostic criteria for depressive episodes met the classification and related diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV);
4. Hamilton Depression Scale (HAMD) 17-item score >=17 points and <24 points;
5. All subjects or their guardians gave informed consent and were willing to participate and sign an informed consent form.

Single patients with temporal lobe epilepsy with a current diagnosis should meet conditions 1 and 2.
Patients with temporal lobe epilepsy with depression should have a current diagnosis that meets conditions 1, 2, 3, and 4; a diagnosis of concomitant depressive seizures (both initial and recurrent) without medication; and a diagnosis of epilepsy that predates the initial depressive seizure by more than six months.
Normal control group: normal healthy volunteers. No epileptic seizures and depressive episodes occurred within six months.

排除标准:

1. 有严重内科疾病患者(包括心血管、消化系统、泌尿系统、免疫系统、呼吸系统等);
2. 有炎症性疾病和免疫系统疾病患者;
3. 有药物滥用病史;
4. 有其他精神疾病,例如精神分裂症、双相障碍、饮食失调症等;
5. 已使用细胞因子类药物或影响细胞因子之类的药物及其他干扰色氨酸代谢通路的药物。

Exclusion criteria:

1. Patients with serious medical diseases (including cardiovascular, digestive, urological, immune, respiratory, etc.);
2. Patients with inflammatory and immune system diseases;
3. Patients with a history of substance abuse;
4. Patients with other psychiatric diseases, such as schizophrenia, bipolar disorder, eating disorders, etc.;
5. Patients who have used cytokine-like drugs or drugs that affect cytokines and such and other drugs that interfere with Tryptophan metabolic pathway drugs.

研究实施时间:

Study execute time:

From 2022-04-01 00:00:00 To 2022-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-04-01 00:00:00 To 2022-09-30 00:00:00

干预措施:

Interventions:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广西壮族自治区 

市(区县):

南宁 

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

Nanning

单位(医院):

广西中医药大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Guangxi University of Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广西壮族自治区 

市(区县):

南宁 

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

Nanning

单位(医院):

广西医科大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Guangxi Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

吲哚 2,3-双加氧酶

指标类型:

主要指标

Outcome:

indoleamine 2,3-dioxygenase

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

犬尿素

指标类型:

主要指标

Outcome:

kynurenine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

色氨酸

指标类型:

主要指标

Outcome:

tryptophan

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

喹啉酸

指标类型:

主要指标

Outcome:

quinolinic acid

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

犬尿酸

指标类型:

主要指标

Outcome:

kynurenic acid

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

3-羟基-2-氨基苯甲酸

指标类型:

主要指标

Outcome:

3-hydroxyanthranilic acid

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

3-羟基犬尿氨酸

指标类型:

主要指标

Outcome:

3-hydroxykynurenine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群

指标类型:

主要指标

Outcome:

Intestinal flora

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不使用随机方法

Randomization Procedure (please state who generates the random number sequence and by what method):

Not using random methods

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2022-03-25 23:15:58